|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CDC73 |
Gene summary for CDC73 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CDC73 | Gene ID | 79577 |
| Gene name | cell division cycle 73 | |
| Gene Alias | C1orf28 | |
| Cytomap | 1q31.2 | |
| Gene Type | protein-coding | GO ID | GO:0000082 | UniProtAcc | Q6P1J9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79577 | CDC73 | LZE4T | Human | Esophagus | ESCC | 3.76e-18 | 5.13e-01 | 0.0811 |
| 79577 | CDC73 | LZE5T | Human | Esophagus | ESCC | 1.74e-06 | 2.06e-01 | 0.0514 |
| 79577 | CDC73 | LZE7T | Human | Esophagus | ESCC | 1.18e-06 | 6.35e-01 | 0.0667 |
| 79577 | CDC73 | LZE8T | Human | Esophagus | ESCC | 3.93e-05 | 9.85e-02 | 0.067 |
| 79577 | CDC73 | LZE20T | Human | Esophagus | ESCC | 1.80e-12 | 2.40e-01 | 0.0662 |
| 79577 | CDC73 | LZE22D1 | Human | Esophagus | HGIN | 1.62e-04 | 9.87e-02 | 0.0595 |
| 79577 | CDC73 | LZE22T | Human | Esophagus | ESCC | 7.34e-12 | 5.50e-01 | 0.068 |
| 79577 | CDC73 | LZE24T | Human | Esophagus | ESCC | 2.19e-17 | 5.52e-01 | 0.0596 |
| 79577 | CDC73 | LZE6T | Human | Esophagus | ESCC | 8.01e-04 | 5.36e-02 | 0.0845 |
| 79577 | CDC73 | P1T-E | Human | Esophagus | ESCC | 3.12e-06 | 4.08e-01 | 0.0875 |
| 79577 | CDC73 | P2T-E | Human | Esophagus | ESCC | 9.50e-32 | 6.39e-01 | 0.1177 |
| 79577 | CDC73 | P4T-E | Human | Esophagus | ESCC | 1.09e-30 | 7.81e-01 | 0.1323 |
| 79577 | CDC73 | P5T-E | Human | Esophagus | ESCC | 1.15e-25 | 5.99e-01 | 0.1327 |
| 79577 | CDC73 | P8T-E | Human | Esophagus | ESCC | 3.36e-23 | 3.21e-01 | 0.0889 |
| 79577 | CDC73 | P9T-E | Human | Esophagus | ESCC | 5.11e-26 | 3.39e-01 | 0.1131 |
| 79577 | CDC73 | P10T-E | Human | Esophagus | ESCC | 8.34e-20 | 4.79e-01 | 0.116 |
| 79577 | CDC73 | P11T-E | Human | Esophagus | ESCC | 1.04e-20 | 6.96e-01 | 0.1426 |
| 79577 | CDC73 | P12T-E | Human | Esophagus | ESCC | 6.11e-13 | 3.65e-01 | 0.1122 |
| 79577 | CDC73 | P15T-E | Human | Esophagus | ESCC | 3.64e-24 | 6.27e-01 | 0.1149 |
| 79577 | CDC73 | P16T-E | Human | Esophagus | ESCC | 1.56e-28 | 7.08e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190331125 | Skin | AK | regulation of mRNA metabolic process | 81/1910 | 288/18723 | 7.27e-18 | 8.61e-15 | 81 |
| GO:002261328 | Skin | AK | ribonucleoprotein complex biogenesis | 108/1910 | 463/18723 | 8.48e-17 | 6.27e-14 | 108 |
| GO:005068420 | Skin | AK | regulation of mRNA processing | 47/1910 | 137/18723 | 1.92e-14 | 7.57e-12 | 47 |
| GO:001605518 | Skin | AK | Wnt signaling pathway | 98/1910 | 444/18723 | 9.39e-14 | 3.09e-11 | 98 |
| GO:019873818 | Skin | AK | cell-cell signaling by wnt | 98/1910 | 446/18723 | 1.26e-13 | 3.72e-11 | 98 |
| GO:007182628 | Skin | AK | ribonucleoprotein complex subunit organization | 61/1910 | 227/18723 | 7.85e-13 | 2.02e-10 | 61 |
| GO:002261828 | Skin | AK | ribonucleoprotein complex assembly | 58/1910 | 220/18723 | 6.75e-12 | 1.33e-09 | 58 |
| GO:003011118 | Skin | AK | regulation of Wnt signaling pathway | 73/1910 | 328/18723 | 9.27e-11 | 1.52e-08 | 73 |
| GO:001604920 | Skin | AK | cell growth | 93/1910 | 482/18723 | 9.55e-10 | 9.42e-08 | 93 |
| GO:005067319 | Skin | AK | epithelial cell proliferation | 86/1910 | 437/18723 | 1.52e-09 | 1.43e-07 | 86 |
| GO:004477210 | Skin | AK | mitotic cell cycle phase transition | 83/1910 | 424/18723 | 3.81e-09 | 3.05e-07 | 83 |
| GO:00198278 | Skin | AK | stem cell population maintenance | 37/1910 | 131/18723 | 5.65e-09 | 4.03e-07 | 37 |
| GO:003164728 | Skin | AK | regulation of protein stability | 64/1910 | 298/18723 | 5.93e-09 | 4.14e-07 | 64 |
| GO:000734616 | Skin | AK | regulation of mitotic cell cycle | 87/1910 | 457/18723 | 6.50e-09 | 4.47e-07 | 87 |
| GO:00987279 | Skin | AK | maintenance of cell number | 37/1910 | 134/18723 | 1.10e-08 | 7.11e-07 | 37 |
| GO:00000828 | Skin | AK | G1/S transition of mitotic cell cycle | 50/1910 | 214/18723 | 1.57e-08 | 9.40e-07 | 50 |
| GO:00165709 | Skin | AK | histone modification | 84/1910 | 463/18723 | 1.10e-07 | 4.95e-06 | 84 |
| GO:00448438 | Skin | AK | cell cycle G1/S phase transition | 52/1910 | 241/18723 | 1.32e-07 | 5.80e-06 | 52 |
| GO:003009928 | Skin | AK | myeloid cell differentiation | 72/1910 | 381/18723 | 1.76e-07 | 7.28e-06 | 72 |
| GO:005067818 | Skin | AK | regulation of epithelial cell proliferation | 72/1910 | 381/18723 | 1.76e-07 | 7.28e-06 | 72 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CDC73 | SNV | Missense_Mutation | c.1073G>A | p.Arg358Gln | p.R358Q | Q6P1J9 | protein_coding | deleterious(0.01) | probably_damaging(0.949) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CDC73 | SNV | Missense_Mutation | c.1352N>T | p.Ala451Val | p.A451V | Q6P1J9 | protein_coding | tolerated(0.06) | benign(0.119) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CDC73 | SNV | Missense_Mutation | c.1019N>C | p.Val340Ala | p.V340A | Q6P1J9 | protein_coding | tolerated(0.78) | benign(0.007) | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| CDC73 | SNV | Missense_Mutation | novel | c.1034N>A | p.Ser345Tyr | p.S345Y | Q6P1J9 | protein_coding | tolerated(0.13) | probably_damaging(0.949) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
| CDC73 | SNV | Missense_Mutation | novel | c.947N>T | p.His316Leu | p.H316L | Q6P1J9 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-AR-A2LN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | SD |
| CDC73 | SNV | Missense_Mutation | c.1247N>A | p.Gly416Asp | p.G416D | Q6P1J9 | protein_coding | deleterious(0.03) | benign(0.03) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| CDC73 | SNV | Missense_Mutation | novel | c.1537N>T | p.Arg513Trp | p.R513W | Q6P1J9 | protein_coding | deleterious(0.02) | possibly_damaging(0.562) | TCGA-BH-A5IZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| CDC73 | SNV | Missense_Mutation | novel | c.72N>C | p.Glu24Asp | p.E24D | Q6P1J9 | protein_coding | tolerated(0.2) | benign(0.003) | TCGA-S3-AA17-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
| CDC73 | SNV | Missense_Mutation | c.921N>G | p.Phe307Leu | p.F307L | Q6P1J9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| CDC73 | SNV | Missense_Mutation | rs878855091 | c.787C>T | p.Arg263Cys | p.R263C | Q6P1J9 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |